Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharmaceutical) has obtained the National Medical Products Administration’s (NMPA) Notice of Approval for Drug Clinical Trials (Notification No. 2026LP01818) for its Class 1 chemical drug LXH-2103 injection. The approval permits the company to launch clinical studies targeting moderate-to-severe postoperative pain, marking a key milestone in the product’s development timeline.

LXH-2103 is formulated as a 1 ml: 50 mg injection and functions as a biased mu-opioid receptor agonist. According to Xinhua Pharmaceutical, the molecule is engineered to mitigate inter-individual variability associated with CYP2D6 genetic polymorphism that often limits the efficacy and safety of conventional opioids such as hydrocodone, codeine, and tramadol. Pre-clinical studies cited by the company indicate strong analgesic potential coupled with an improved safety profile.

The regulatory journey began with an NMPA consultation request in November 2025, followed by CDE feedback in March 2026. The formal clinical-trial application was accepted on 9 April 2026 and cleared in June 2026. The company will now conduct clinical trials in accordance with the approved protocol and, upon completion, submit full study data for production registration.

Management highlights that drug development timelines remain subject to clinical, technical, and regulatory uncertainties. Xinhua Pharmaceutical has pledged to disclose material updates in line with statutory requirements. Investors are advised to monitor subsequent announcements for progress updates on LXH-2103.